EVP-ABD-enhanced MRI to evaluate diffuse liver disease in a rat model

    loading  Checking for direct PDF access through Ovid


PurposeTo evaluate the feasibility of using manganese-based MR imaging contrast agent EVP-ABD to detect diffuse liver disease in an established rat hepatitis model.Materials and MethodsHepatitis was induced by administration of CCl4 in corn oil vehicle to rats intraperitoneally. MR images were acquired on a 3T scanner using a volume coil ≈36 hours after the administration of CCl4. EVP-ABD was administered via a tail vein at a dose of 10 μmol/kg. Multi-TI turboflash images were acquired to evaluate liver R1 (=1/T1) values before and after the EVP-ABD administration. Eighteen rats received various doses of CCl4 and completed pre- and postcontrast MRI scans and liver histologic evaluation.ResultsThe liver R1 after the EVP-ABD administration and the change of the liver R1 before and after the administration, ΔR1, show significant correlations with the CCl4 dose. A significant correlation was also found between the histologic scores and the CCl4 doses despite known variability in the relationship of CCl4 dose to histology. A significant correlation was found between the histologic score and ΔR1.ConclusionOur results indicate that EVP-ABD-enhanced MRI can detect diffuse liver disease generated by CCl4 based on the significant correlation between proton R1 in liver following EVP-ABD and the CCl4 doses as well as the histologic scores. J. Magn. Reson. Imaging 2008;27:1317–1321. © 2008 Wiley-Liss, Inc.

    loading  Loading Related Articles